ZFHX3 and non-small cell lung carcinoma: In the previous studies, PTPRD/PTPRT mutation and ZFHX3 mutation were reported to be protective biomarker for ICI treatment in NSCLC patients (Bindea et al., 2013; Zhang et al., 2021).